Amneal Q2 FY26 GAAP net income more than doubles to $58 million; revenue rises 10% to $796 million - AMRX News | RalliesAmneal Q2 FY26 GAAP net income more than doubles to $58 million; revenue rises 10% to $796 million
A
AMRX• Q2 revenue and earnings rise
- Amneal Pharmaceuticals Q2 2026 net revenue rose 10% to $796 million.
- GAAP net income attributable to shareholders more than doubled to $58 million; GAAP diluted EPS more than doubled to $0.18.
- Non-GAAP adjusted EBITDA climbed 12% to $206 million; non-GAAP adjusted diluted EPS increased 20% to $0.30.
Debt repricing and outlook raised
- July debt repricing cut Term Loan B pricing to SOFR+250 bps from SOFR+300 bps, targeting about $12 million in annual cash interest savings.
- Amneal raised its 2026 outlook: net revenue of $3.1 billion-$3.2 billion and non-GAAP adjusted EBITDA of $750 million-$780 million.
•
